RASSF2

Ras association domain-containing protein 2 · P50749 · RASSF2 on Sugi Atlas →

0 patent compounds predicted against RASSF2, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to RASSF2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
NEO100 and High-Grade Meningioma PHASE2RECRUITING
BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer PHASE2COMPLETED
Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1 PHASE2COMPLETED
Evaluate the Efficacy of Sorafenib in Renal Cell Carcinoma Patients After a Radical Resection of the Metastases PHASE2UNKNOWN
Antioxidant Therapy With N-acetylcysteine for Learning and Motor Behavior in Children With Neurofibromatosis Type 1 PHASE2COMPLETED
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma PHASE1/PHASE2COMPLETED
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer PHASE2COMPLETED
Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation PHASE2COMPLETED
R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas PHASE2COMPLETED
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma PHASE1/PHASE2SUSPENDED
Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma (PENILANE) PHASE2WITHDRAWN
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure PHASE2COMPLETED
Phase I - Escalating Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Locally Advanced Adenocarcinoma of the Pancreas, and a Single Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Non-operable Adenocarcinoma of the Pancreas PHASE1COMPLETED
Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors PHASE1COMPLETED
Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies PHASE1RECRUITING
Expression and Function of the Renin-Angiotensin System in the Esophagus EARLY_PHASE1COMPLETED
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies nanRECRUITING
Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial nanRECRUITING
Novel Biomarkers in the Neoplastic Progression of Barrett's Esophagus nanACTIVE_NOT_RECRUITING
Clinical Genetics Branch Eligibility Screening Survey nanNOT_YET_RECRUITING
Long Term Prediction of MASH-related HCC Risk by Proteomics nanNOT_YET_RECRUITING
Characterisation of Gene Variants in the Angiogenic Pathway nanUNKNOWN
Prospective Validation of a DNA Damage Repair-Hippo Pathway Signature in Patients With Advanced Gastric Cancer nanUNKNOWN
Renal Artery Dopplers in Twin Twin Transfusion Syndrome nanCOMPLETED
Long QT Syndrome-Population Genetics and Cardiac Studies nanCOMPLETED
Studying Tissue Samples From Patients With Stage II Colon Cancer Treated on Clinical Trial CLB-9581 nanCOMPLETED
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants. nanUNKNOWN
Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment nanACTIVE_NOT_RECRUITING
Analysis of Intestinal Microflora Combined With DNA Methylation in Stool to Detect Colorectal Cancer nanUNKNOWN
Genetics of Hypertension in Blacks nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a RASSF2 binder may also engage these)

ProteinNameSimilarity
Q3B7D5 1.000 Q3B7D5 →
Q9H2L5 0.997 Q9H2L5 →
Q8BMS9 0.994 Q8BMS9 →
Q8CB96 0.990 Q8CB96 →
Q566C5 0.988 Q566C5 →
Q99P51 0.982 Q99P51 →
Q86WH2 0.970 Q86WH2 →
RASSF5 Ras association domain-containing protein 5 0.967 landscape →
Q9Z1N9 0.967 Q9Z1N9 →
Q6QD73 0.967 Q6QD73 →
Q99MK9 0.967 Q99MK9 →
MAPKAP1 Target of rapamycin complex 2 subunit MAPKAP1 0.966 landscape →
Q66H91 0.966 Q66H91 →
Q4KUS2 0.966 Q4KUS2 →
O35141 0.966 O35141 →
Q5EBH1 0.966 Q5EBH1 →
Q7ZYH1 0.965 Q7ZYH1 →
Q9UPW8 0.965 Q9UPW8 →
O14795 0.965 O14795 →
Q6AYF1 0.965 Q6AYF1 →
Q8BHD4 0.964 Q8BHD4 →
Q66T02 0.964 Q66T02 →
Q5R803 0.964 Q5R803 →
Q62768 0.964 Q62768 →
Q9Z1T4 0.963 Q9Z1T4 →
Q5RDV5 0.963 Q5RDV5 →
Q62769 0.963 Q62769 →
Q8BKH7 0.963 Q8BKH7 →
Q9W6S3 0.963 Q9W6S3 →
Q01826 0.963 Q01826 →